Literature DB >> 17321995

FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation.

Kazue Arimoto1, Norimitsu Kadowaki, Takayuki Ishikawa, Tatsuo Ichinohe, Takashi Uchiyama.   

Abstract

CD4+CD25+ regulatory T-cells (Treg cells) that express Foxp3 protein play an important role in inducing and maintaining allogeneic tolerance and can inhibit graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT) in murine models. Thus, it is important to clarify the kinetics of Treg cell recovery and its correlation with the occurrence of GVHD in humans; however, whether there is a correlation between the frequency of Treg cells in peripheral blood and the occurrence of GVHD is controversial. We examined the recovery of Treg cells in peripheral blood after allogeneic SCT by quantitating FOXP3 messenger RNA (mRNA). Full donor chimerism was achieved within 1 month after SCT in all but 1 case. The ratios of the measured expression levels of FOXP3 mRNA to those of endogenous control genes rapidly recovered to the normal range as early as 1 month after SCT. Cross-sectional as well as longitudinal analyses revealed no significant correlation between the expression level of FOXP3 mRNA and the occurrence of acute and chronic GVHD. This study suggests that the level of FOXP3+ cells is normal relative to other cell types from the early period after SCT and that their frequency in peripheral blood relative to total leukocytes or T-cells is not indicative of the occurrence of GVHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17321995     DOI: 10.1532/IJH97.06160

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  30 in total

Review 1.  Current recommendations for positive controls in RT-PCR assays.

Authors:  T Lion
Journal:  Leukemia       Date:  2001-07       Impact factor: 11.528

2.  Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD.

Authors:  Kathrin Rieger; Christoph Loddenkemper; Jochem Maul; Thomas Fietz; Daniel Wolff; Harald Terpe; Beate Steiner; Erika Berg; Stephan Miehlke; Martin Bornhäuser; Thomas Schneider; Martin Zeitz; Harald Stein; Eckhard Thiel; Rainer Duchmann; Lutz Uharek
Journal:  Blood       Date:  2005-11-08       Impact factor: 22.113

3.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

4.  Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation.

Authors:  Véronique Meignin; Régis Peffault de Latour; Julien Zuber; Armelle Régnault; Nicolas Mounier; Fabrice Lemaître; Hélène Dastot; Raphaël Itzykson; Agnès Devergie; Ana Cumano; Eliane Gluckman; Anne Janin; Antonio Bandeira; Gérard Socié
Journal:  Exp Hematol       Date:  2005-08       Impact factor: 3.084

5.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

6.  Differential expression of IFN-alpha subtypes in human PBMC: evaluation of novel real-time PCR assays.

Authors:  S Löseke; E Grage-Griebenow; A Wagner; K Gehlhar; A Bufe
Journal:  J Immunol Methods       Date:  2003-05-01       Impact factor: 2.303

7.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Authors:  E Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; E Delabesse; E Macintyre; E Gottardi; G Saglio; F Watzinger; T Lion; J J M van Dongen; P Hokland; J Gabert
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

8.  Association of Foxp3 regulatory gene expression with graft-versus-host disease.

Authors:  Yuji Miura; Christopher J Thoburn; Emilie C Bright; Michele L Phelps; Tahiro Shin; Elizabeth C Matsui; William H Matsui; Sally Arai; Ephraim J Fuchs; Georgia B Vogelsang; Richard J Jones; Allan D Hess
Journal:  Blood       Date:  2004-06-01       Impact factor: 22.113

9.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  7 in total

Review 1.  Therapeutic use of regulatory T cells for graft-versus-host disease.

Authors:  Shlomo Elias; Alexander Y Rudensky
Journal:  Br J Haematol       Date:  2019-08-16       Impact factor: 6.998

2.  Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.

Authors:  Katie Matthews; ZiYi Lim; Behdad Afzali; Laurence Pearce; Atiyeh Abdallah; Shahram Kordasti; Antonio Pagliuca; Giovanna Lombardi; J Alejandro Madrigal; Ghulam J Mufti; Linda D Barber
Journal:  Haematologica       Date:  2009-06-02       Impact factor: 9.941

Review 3.  Biology of chronic graft-versus-host disease: implications for a future therapeutic approach.

Authors:  Paul J Martin
Journal:  Keio J Med       Date:  2008-12

4.  Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease.

Authors:  Xiao Chen; Sanja Vodanovic-Jankovic; Bryon Johnson; Melissa Keller; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2007-08-10       Impact factor: 22.113

5.  The role of regulatory T cells in the biology of graft versus host disease.

Authors:  Amy J Beres; William R Drobyski
Journal:  Front Immunol       Date:  2013-06-24       Impact factor: 7.561

6.  Integrative genomics in combination with RNA interference identifies prognostic and functionally relevant gene targets for oral squamous cell carcinoma.

Authors:  Chang Xu; Pei Wang; Yan Liu; Yuzheng Zhang; Wenhong Fan; Melissa P Upton; Pawadee Lohavanichbutr; John R Houck; David R Doody; Neal D Futran; Lue Ping Zhao; Stephen M Schwartz; Chu Chen; Eduardo Méndez
Journal:  PLoS Genet       Date:  2013-01-17       Impact factor: 5.917

7.  Characterizing T cells in SCID patients presenting with reactive or residual T lymphocytes.

Authors:  Atar Lev; Amos J Simon; Luba Trakhtenbrot; Itamar Goldstein; Meital Nagar; Polina Stepensky; Gideon Rechavi; Ninette Amariglio; Raz Somech
Journal:  Clin Dev Immunol       Date:  2012-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.